These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35727633)

  • 21. [An exploratory clinical study of the efficacy and safety of tumor-infiltrating lymphocytes in the treatment of metastatic osteosarcoma].
    Wang CR; Kang M; Xu J; Lyu Y; Jiang YF; Sun MX; Zuo DQ; Shen JK; Ma XJ; Sun W; Hua YQ; Cai Z
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2421-2427. PubMed ID: 36000370
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
    Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
    Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
    Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
    Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.
    Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA
    J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
    Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
    Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.
    Guo J; Luo N; Ai G; Yang W; Zhu J; Li C; Chen R; Zhang C; Liu S; Jin H; Cheng Z
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35177415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of adjuvant chemotherapy after concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
    Kou L; Zhang T; Yang X; Peng S; Wang Y; Yuan M; Li M
    Future Oncol; 2022 May; 18(16):1917-1915. PubMed ID: 35193379
    [No Abstract]   [Full Text] [Related]  

  • 34. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.
    Saint-Jean M; Knol AC; Volteau C; Quéreux G; Peuvrel L; Brocard A; Pandolfino MC; Saiagh S; Nguyen JM; Bedane C; Basset-Seguin N; Khammari A; Dréno B
    J Immunol Res; 2018; 2018():3530148. PubMed ID: 29750176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.
    Borch TH; Harbst K; Rana AH; Andersen R; Martinenaite E; Kongsted P; Pedersen M; Nielsen M; Kjeldsen JW; Kverneland AH; Lauss M; Hölmich LR; Hendel H; Met Ö; Jönsson G; Donia M; Svane IM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34210820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous Tumor-Infiltrating Lymphocyte Mono-Therapy Can Rapidly Shrank Tumor in Asian Patient with Stage III/IV Cervical Cancer: Two Cases Report.
    Li F; Wang Y; Yan J; Wu H; Du X; Feng W; Zhang X; Xue Y; Wang H; Liu W
    Int J Womens Health; 2024; 16():31-39. PubMed ID: 38222312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study.
    Atci MM; Akagunduz B; Demir M; Dönmez Yilmaz B; Akin Telli T; Can O; Cil I; Goktas Aydın S; Ozyurt N; Onder AH; Selvi O; Sakin A
    Oncol Res Treat; 2022; 45(5):254-261. PubMed ID: 35034017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
    Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
    BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
    Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.